Skip to main content
. 2023 Mar 28;15(4):1085. doi: 10.3390/pharmaceutics15041085

Figure 6.

Figure 6

Effect of S63845 treatment on lymphoid differentiation in CB6F1 mice. (A) Representative FACS profiles and percentages of CLP, CD3e+, B220+, and NK1.1+ subpopulations in BM cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (B) Representative FACS profiles and percentages of CLP, CD3e+, B220+, and NK1.1+ subpopulations in BM cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (C) Representative FACS profiles and percentages of CLP, CD3e+, B220+, and NK1.1+ subpopulations in SP cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (D) Representative FACS profiles and percentages of CLP, CD3e+, B220+, and NK1.1+ subpopulations in SP cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (E) Representative FACS profiles and percentages of CD3e+, B220+, and NK1.1+ subpopulations in PB cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (F) Representative FACS profiles and percentages of CD3e+, B220+, and NK1.1+ subpopulations in PB cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. All data represent the means ± SEM compared with control unless otherwise specified. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns = not significant by two-tailed unpaired Students’ t-test. CLP: common lymphoid progenitor; LKS: Lin−c-KitLowSca-1Low.